lifestyle.longislandreport.org

Author: Edgewise Therapeutics

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

January 5, 2026
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy

December 24, 2025
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

November 26, 2025
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 14, 2025
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

November 5, 2025